Pharming Group N V Revenue Growth Rates (PHAR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pharming Group N v   (NASDAQ: PHAR)
 

PHAR's Revenue Growth by Quarter and Year

Pharming Group N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHAR Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 375.63
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 375.63

PHARs Annual Revenue
Pharming Group N V 's Revenue in the fiscal year 2025 $ 375.63 millions
Pharming Group N V 's Revenue in the fiscal year 2024 $ 296.80 millions
Pharming Group N V 's Revenue in the fiscal year 2023 $ 245.10 millions
Pharming Group N V 's Revenue in the fiscal year 2022 $ 205.62 millions
Pharming Group N V 's Revenue in the fiscal year 2021 $ 198.87 millions




PHAR Revenue fourth quarter 2025 Y/Y Growth Comment
Pharming Group N V showed record Revenue growth in the fourth quarter 2025 with 26.56% from the fourth quarter 2025 2024, to $ 375.63 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 86 other companies have achieved higher Revenue growth. While Pharming Group N V ' s Revenue rise of 26.56% ranks overall at the positon no. 898 in the fourth quarter 2025.


PHAR Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 26.56 % 21.09 % 19.2 % 3.39 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   26.56 % 21.09 % 19.2 % -

Financial Statements
Pharming Group N V 's fourth quarter 2025 Revenue $ 375.63 millions PHAR's Income Statement
Pharming Group N V 's fourth quarter 2024 Revenue $ 296.80 millions Quarterly PHAR's Income Statement


PHAR Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   26.56 % 21.09 % 19.2 % -


Back to PHAR Growth rate Comparisons >> Back to PHAR Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #201
Overall #898

Revenue Y/Y Growth Statistics
High Average Low
26.56 % 13.17 % -4.38 %
(Dec 31 2023)   (Dec 31 2021)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #201
Overall #898
Revenue Y/Y Growth Statistics
High Average Low
26.56 % 13.17 % -4.38 %
(Dec 31 2023)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Pharming Group N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PHAR's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PHAR's IV. Quarter Q/Q Revenue Comment


Pharming Group N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 375.63 $ 296.80 $ 245.10 $ 205.62 $ 198.87
Y / Y Revenue Growth (TTM) 26.56 % 21.09 % 19.2 % 3.39 % -4.38 %
Year on Year Revenue Growth Overall Ranking # 2506 # 2702 # 2000 # 0 # 0
Seqeuential Revenue Change (TTM) 26.56 % 21.09 % 19.2 % 3.39 % -4.38 %
Seq. Revenue Growth (TTM) Overall Ranking # 823 # 2702 # 2000 # 0 # 0


Cumulative Revenue growth Comment
Pharming Group N V saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 26.56% year on year, to $ 376 millions if the fiscal year would have ended in Dec 31 2025.
Pharming Group N V 's trailing twelve months Revenue growth was higher than company's average 6.07% and higher than 21.09% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 26.56 % increase from $296.8 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 354 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2506, from total ranking in previous quarter at 2702.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 355
Overall # 2506

Revenue TTM Y/Y Growth Statistics
High Average Low
19.2 %
 6.07 %
-4.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 167
S&P 500 # 823
Cumulative Revenue growth Comment
Pharming Group N V saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 26.56% year on year, to $ 376 millions if the fiscal year would have ended in Dec 31 2025.
Pharming Group N V 's trailing twelve months Revenue growth was higher than company's average 6.07% and higher than 21.09% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 26.56 % increase from $296.8 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 354 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2506, from total ranking in previous quarter at 2702.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 355
Overall # 2506

Revenue TTM Y/Y Growth Statistics
High Average Low
19.2 %
6.07 %
-4.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 167
S&P 500 # 823




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PHAR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Electrocore Inc 46.11%$ 46.111 millions
Mannkind Corporation45.82%$ 45.820 millions
Hologic Inc44.84%$ 44.836 millions
Ensysce Biosciences Inc 44.39%$ 44.389 millions
Profound Medical Corp 43.13%$ 43.127 millions
Regenxbio Inc 43.00%$ 43.005 millions
Xeris Biopharma Holdings Inc 42.78%$ 42.776 millions
Eli Lilly And Company42.56%$ 42.557 millions
Edwards Lifesciences Corporation42.48%$ 42.484 millions
Rani Therapeutics Holdings Inc 42.12%$ 42.121 millions
Establishment Labs Holdings Inc 41.85%$ 41.854 millions
The Oncology Institute Inc 41.58%$ 41.579 millions
Cytosorbents Corporation41.55%$ 41.553 millions
Vystar Corporation41.19%$ 41.186 millions
Prelude Therapeutics Inc41.00%$ 41.000 millions
Biodesix Inc 40.76%$ 40.756 millions
Ligand Pharmaceuticals Incorporated40.01%$ 40.008 millions
Femasys Inc 39.84%$ 39.844 millions
Natera Inc 39.79%$ 39.793 millions
Guardant Health Inc 39.37%$ 39.369 millions
Innovative Eyewear Inc 38.96%$ 38.964 millions
Ceribell Inc 38.36%$ 38.357 millions
Gsk Plc37.35%$ 37.347 millions
Rapid Micro Biosystems Inc 37.28%$ 37.284 millions
Nexgel Inc 36.92%$ 36.918 millions
Rhythm Pharmaceuticals Inc 36.87%$ 36.871 millions
Adc Therapeutics Sa36.36%$ 36.357 millions
Logicmark Inc36.29%$ 36.290 millions
Biofrontera Inc 36.16%$ 36.157 millions
Butterfly Network Inc 35.74%$ 35.743 millions


About Pharming Group N V Revenue Growth Rates (PHAR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pharming Group N V (CIK 1828316).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001828316-26-000015
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pharming Group N V’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.